Rationale for targeted therapies in hepatocellular carcinoma

@article{Faivre2008RationaleFT,
  title={Rationale for targeted therapies in hepatocellular carcinoma},
  author={Sandrine J. Faivre and Chantal Dreyer and Ghassan Maalouf and Marie-Paule Sablin and Eric Raymond},
  journal={Targeted Oncology},
  year={2008},
  volume={3},
  pages={81-85}
}
Recent results showing survival improvement with sorafenib, a multitargeted kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) suggest the important role of vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/Ras signaling in this disease. In preclinical studies, hypoxia, along with vascular endothelial growth factor (VEGF) and VEGFR strongly promote angiogenesis in multiple models including HCC. VEGF and VEGFR, other… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)

  • SJ Faivre
  • Proc Am Soc Clin Oncol Abstract
  • 2007
1 Excerpt

Molecular basis for sunitinib efficacy and future clinical development

  • S Faivre
  • Nat Rev Drug Discov
  • 2007
1 Excerpt

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  • AX Zhu
  • Cancer
  • 2007
1 Excerpt

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  • MB Thomas
  • Cancer
  • 2007
1 Excerpt

Sirolimus retards growth of hepatocellular cancer

  • M Rizell, C Cahlin, S Friman
  • Proc Fifth International Meeting on…
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…